{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-044325","form_type":"8-K","ticker":"RNAZ","cik":"0001829635","company_name":"Transcode Therapeutics, Inc.","filed_at":"2024-04-05T23:59:59+00:00","discovered_at":"2026-05-14T18:03:20.487422+00:00","generated_at":"2026-06-04T01:56:00.601905+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"TransCode Therapeutics reports FY2023 operating loss of $19.4M; cash $2.8M at year-end","bullets":["Cash $2.8M as of Dec 31, 2023; net $6.2M raised in Jan 2024; funding expected into late Q3/Q4 2024.","R&D expenses $12.3M (up from $10.2M in 2022); G&A $7.2M (down from $8.4M); operating loss $19.4M.","CEO Michael Dudley resigned; CFO Tom Fitzgerald named interim CEO; Philippe Calais appointed Executive Chairman.","Phase 0 trial of TTX-MC138 completed; preliminary results suggest delivery to metastatic lesions in breast cancer patient.","Phase 1 trial of TTX-MC138 planned mid-2024 subject to FDA authorization and IRB approvals."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-044325","json":"https://secwatch.observer/filing/0001104659-24-044325.json","markdown":"https://secwatch.observer/filing/0001104659-24-044325.md","text":"https://secwatch.observer/filing/0001104659-24-044325.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1829635/000110465924044325/0001104659-24-044325-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1829635/000110465924044325/tm2411028d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T01:56:00.601905+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"bdf7e7ed4385bdc37860db87585758b28e324eae","claim":"Transcode Therapeutics, Inc. reported financial results for the fiscal year ended December 31, 2023.","evidence_excerpt":"On April 3, 2024, TransCode Therapeutics, Inc. issued a press release announcing its financial results and other business highlights for the fourth quarter and full year ended December 31, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1829635/000110465924044325/0001104659-24-044325-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fiscal year ended December 31, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}